Relay Therapeutics Hits New 52-Week High at $19.93, Up 162%

Relay Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 19.93 on June 29, 2026. This achievement marks a remarkable increase in the stock's performance, with a year-over-year gain of 162.15%, significantly outpacing the S&P 500's performance of 20.53% during the same period. The company's market capitalization stands at USD 1,716 million, reflecting its position within the small-cap segment. Despite being a loss-making entity, Relay Therapeutics has demonstrated resilience in the market, as indicated by its substantial price appreciation from a 52-week low of USD 3.03. Key financial metrics reveal a price-to-book ratio of 3.03, while the company currently does not offer a dividend yield. The debt-to-equity ratio is reported at -0.97, and the return on equity stands at -48.76%. This recent price movement underscores Relay Therapeutics' evolving market dynamics and its potential role within the biotechnology landscape.